 |
Tuesday, April 6, 2010
12 noon – 1:30pm
Le Meridien Hotel
20 Sidney St., Cambridge, MA 02139
12:00 – 12:05: Introduction
Chris Burns, Ph.D. Vice President Assay Research & Development, Aushon BioSystems
12:05 – 12:45: Presentation
“Using Biomarkers to Accelerate Oncology Clinical Development”
Dr. Michael Shi, Senior Director of Oncology Biomarkers in Oncology Translational Medicine, Novartis Pharmaceuticals Corp.
Abstract: Biomarker-based drug development has already been proven to be a successful strategy in the development of novel anticancer drugs such as Gleevec®. This talk will discuss the application of biomarkers in developing targeted therapeutics and address the following key challenges and investment opportunities:
- To verify the impact of novel drugs on targets/pathways by
monitoring pharmacodynamic biomarkers
- To evaluate molecular response as an early clinical efficacy read-out
- To increase drug development predictability
- To give the right drug to the right patients at the optimal dos
Read Full Abstract>>
12:45-1:15: Lunch Presentation*
“New Targets in Oncology for Biomarker Discovery”
Chris Burns, Ph.D. Vice President, Assay Research & Development, Aushon BioSystems
Abstract: With a new focus in oncology, we have expanded our menu to
include many new soluble factors that are
implicated in angiogenesis and tissue remodeling. Learn more about Aushon's technology, array
validation and the latest oncology and angiogenic targets that you can quantitatively measure. Read Full Abstract>>
|
 |
Seating is limited, so
Dr. Michael ShiFull Bio>>Christine Burns, Ph.D
Full Bio>>
|
